TYMS and neoplasm: While TS inhibitors remain cornerstone agents in cancer chemotherapy, persistent challenges—including resistance, off-target toxicity, and limited tumor selectivity—continue to limit their therapeutic impact.126,127 Recent developments in medicinal chemistry, structural biology, and cancer pharmacology highlight several promising directions that may reshape TS-targeted therapy.128,129